- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer Strikes USD 2.6 Billion Deal With China's Starna Therapeutics for CAR-T Autoimmune Therapies
PfizerBengaluru: Pfizer said on Wednesday it had struck an exclusive licensing agreement with China's Starna Therapeutics to develop three CAR-T therapies for autoimmune diseases, in a deal worth up to USD 2.6 billion.
The deal marks another bet on a Chinese biotech by the pharma major as it seeks to reignite growth by 2028 while preparing for a wave of patent expirations and continued declines in COVID-related revenue.
Pfizer will pay Starna $330 million upfront and could pay up to $2.3 billion more if the treatments meet development, regulatory and sales milestones. The therapies have not yet entered human trials.
Starna would also receive royalties on sales of any approved products.
The agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities.
In vivo CAR-T therapies are designed to genetically reprogram immune cells directly inside the body, allowing them to target and eliminate disease-causing immune cells.
By contrast, conventional CAR-T treatments involve the complex process of collecting and re-engineering a patient’s cells outside the body before reinfusing them.
The deal follows Pfizer’s $10.5 billion agreement with Innovent Biologics in May and an earlier deal with China’s 3SBio in 2025.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

